Loading...
XNASTBPH
Market cap481mUSD
Dec 23, Last price  
9.79USD
1D
2.09%
1Q
22.07%
Jan 2017
-69.29%
IPO
-55.44%
Name

Theravance Biopharma Inc

Chart & Performance

D1W1MN
XNAS:TBPH chart
P/E
P/S
8.38
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
0.49%
Rev. gr., 5y
-1.00%
Revenues
57m
+11.84%
130,145,000226,00011,688,00042,126,00048,648,00015,386,00060,370,00073,414,00071,857,00055,311,00051,346,00057,424,000
Net income
-55m
L-40.54%
-9,575,000-156,284,000-237,038,000-182,219,000-190,669,000-285,405,000-215,524,000-236,455,000-278,017,000-199,426,000-92,824,000-55,193,000
CFO
-27m
L-85.56%
-119,107,000-120,959,000-175,155,000-168,857,000-98,989,000-201,052,000-112,867,000-238,197,000-250,403,000-207,858,000-186,991,000-26,997,000
Earnings
Feb 24, 2025

Profile

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
IPO date
May 16, 2014
Employees
111
Domiciled in
KY
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
57,424
11.84%
51,346
-7.17%
55,311
-23.03%
Cost of revenue
151,337
137,054
200,943
Unusual Expense (Income)
NOPBT
(93,913)
(85,708)
(145,632)
NOPBT Margin
Operating Taxes
5,924
9
(151)
Tax Rate
NOPAT
(99,837)
(85,717)
(145,481)
Net income
(55,193)
-40.54%
(92,824)
-53.45%
(199,426)
-28.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
(199,551)
(131,478)
102,590
BB yield
32.10%
15.92%
-13.37%
Debt
Debt current
7,846
28,715
17,443
Long-term debt
94,395
119,529
704,756
Deferred revenue
192
310
Other long-term liabilities
99,001
27,095
2,730
Net debt
(185)
(180,076)
481,197
Cash flow
Cash from operating activities
(26,997)
(186,991)
(207,858)
CAPEX
(2,488)
(572)
(3,406)
Cash from investing activities
(32,697)
1,154,009
124,494
Cash from financing activities
(198,933)
(758,806)
91,860
FCF
(81,405)
(75,090)
(168,377)
Balance
Cash
102,426
327,484
173,465
Long term investments
836
67,537
Excess cash
99,555
325,753
238,236
Stockholders' equity
(909,169)
(853,925)
(1,726,042)
Invested Capital
1,274,247
1,397,134
2,060,027
ROIC
ROCE
EV
Common stock shares outstanding
55,303
73,591
69,461
Price
11.24
0.18%
11.22
1.54%
11.05
-37.82%
Market cap
621,606
-24.72%
825,691
7.58%
767,544
-30.72%
EV
621,421
645,615
1,248,741
EBITDA
(89,657)
(78,684)
(135,924)
EV/EBITDA
Interest
2,350
6,369
46,889
Interest/NOPBT